Real-world treatment outcomes of aflibercept versus bevacizumab for neovascular age-related macular degeneration. [PDF]
Mhmud H +8 more
europepmc +1 more source
Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial. [PDF]
Koizumi H +19 more
europepmc +1 more source
Evaluation of aflibercept treatment outcomes using optical coherence tomography angiography in macular telangiectasia type 1. [PDF]
Gezginaslan TA +4 more
europepmc +1 more source
Multimodal imaging biomarkers associated with recurrence of diabetic macular edema during aflibercept treat-and-extend therapy. [PDF]
Kim K, Lee J, Choi J, Yu SY.
europepmc +1 more source
Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions. [PDF]
Sheth JU.
europepmc +1 more source
Optimal Treatment of Retinal Vein Occlusion: An Updated Canadian Review and Recommendations. [PDF]
Sivachandran N +4 more
europepmc +1 more source
Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification. [PDF]
Bartolomeo N +7 more
europepmc +1 more source

